Clinical Trial

Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments. Patients will be randomly assigned to one of two dosing schedules: EMB-01 once weekly, or once weekly for 6 weeks then every two weeks.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-17; most recent amendment 2026-03-02.
Trial Details
NCT Number NCT07314294
Lead Sponsor Shanghai EpimAb Biotherapeutics Co., Ltd.
Conditions Metastatic Colorectal Cancer
Enrollment 54 participants
Start Date 2025-12-18
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-03